FEATURES OF MELATONINE-FORMING FUNCTION OF EPIPHYSIS AND DYSLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE 5 D STAGE
Objective: to analyze the blood lipid spectrum of patients with chronic kidney disease (CKD) 5D stage and to determine the relationship of dyslipidemia with melatoninforming function of the pineal gland (MFE).
Material and methods: 130 people (gender, m – 65) at the age of 58.5 were examined [43; 66] years who are on continuous treatment with hemodialysis. All patients were examined in a laboratory – general and biochemical blood tests were taken, a lipid profile was determined, daily and nighttime levels of melatonin in saliva were measured, and office blood pressure was measured.
Results and discussion: A significant prevalence of MFE disorders in hemodialysis patients and its relationship with the blood lipid spectrum were determined. The negative correlation between the night level of melatonin and total cholesterol (r = -0.26; p <0.05), the negative correlation with triglycerides (r = -0.27; p <0.05), the positive correlation with lipoproteins were determined high density and MFE (r = 0.33; p <0.05). An analysis of the results of a study of lipid metabolism in hemodialysis patients revealed the presence of an increased concentration of total cholesterol, triglycerides, low density lipoprotein fractions and a low content of high density lipoproteins. Patients with impaired MFE have significantly higher levels of total cholesterol, triglycerides, low density lipoproteins, and lower levels of high-density lipoproteins compared to group II.
Conclusions: For patients with CKD stage 5D treated with the method of hemodialysis, there are pronounced disorders of lipid metabolism (58%). In patients with renal replacement therapy, disorders of lipid metabolism are associated with melatonin-forming function of the epiphysis, levels of systolic and diastolic blood pressure, duration of hypertension, hemoglobin level, and duration of hemodialysis treatment.
2. Anwar M. J., Muhammad B. Y., Bader A. A., Abdulghani, M., Mahmood, D., & Haider, M. An insight into the scientific background and future perspectives for the potential uses of melatonin// Egyptian Journal of Basic and Applied Sciences. – 2015. – Vol. 2. – P. 139-152.
3. Jardine A. G., Schmieder R. E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis// N. Engl. J. Med. – 2009. – Vol. 360 (14). – P. 1395-1407
4. Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis//
J. Atheroscler Thromb. – 2013. – Vol. 20(2). – P. 123-133.
5. KGIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney DiseaseKidney//International supplements. – 2013. – Vol. 3.
6. Mohammed І.N., Alwahami А.А. Dyslipidemia in chronic renal failure// Muthanna Medical Journal. – 2018. – Vol. 5(2). – P. 66-85.
7. Slawik H., Stoffel M., Riedl L. Prospective Study on Salivary Evening Melatonin and Sleep before and after Pinealectomy in Humans// J. Biological Rhythms. – 2016; Vol. 31(1). – P. 82-93.
8. Sun H, Huang F-f, Qu S. Melatonin: a potential intervention for hepatic steatosis// Lipids Health Dis. – 2015. Vol. 14(1). – P. 75.
9. Сериков В.С., Ляшев Ю.Д. Влияние мелатонина на изменения липидного обменя при имобилизацинном стрессе// Курский научно-практический вестник «Человек и его здоровье». – 2016. – № 2. – С. 81-84.
10. Смирнов А.В., Добронравов В.А., Каюков И.Г. Эпидемиология и социально-экономические аспекты хронической болезни почек// Нефрология. – 2006. – Т.10, № 1. – С. 7-13.
This work is licensed under a Creative Commons Attribution 4.0 International License.